scholarly journals Post-COVID-19 transient hypogonadism and erectile dysfunction

2021 ◽  
Vol 14 (3) ◽  
pp. 112-118
Author(s):  
F.R. Asfandiyarov ◽  
◽  
V.A. Kruglov ◽  
S.V. Vybornov ◽  
K.S. Seidov ◽  
...  
Keyword(s):  
Erectile Dysfunction ◽  
Testosterone Level ◽  
Erectile Function ◽  
Hormone Replacement ◽  
Severe Illness ◽  
Hormonal Profile ◽  
Group 2 ◽  
The Impact ◽  
Group 1

Introduction. The SARS-CoV-2 virus pandemic is one of the biggest public health challenges in the modern era. Currently, along with the continuing high incidence rate, the immediate and long-term consequences of COVID-19 are predictably becoming increasingly important. The impact of the COVID-19 on andrological health and erectile function has been studied insufficiently. The aim of this study was to assess the impact of COVID-19 infection on erectile function. Material and methods. From May 2020 to April 2021 44 men after COVID-19 pneumonia were consulted for decrease in libido, erectile function and the quality of sexual intercourse in three Astrakhan medical centers. The examination of patients included standard general clinical methods, hormonal profile studying (testosterone, luteinizing homone, prolactin) and number of standardized questionnaires. Results. No changes in the levels of luteinizing hormone and prolactin were observed. Total testosterone levels ranged from 8.0 to 14.8 nmol / L. According the testosterone level patients were divided into two groups. In group 1 patients testosterone level was 12.0 nmol/L and more, in group 2 patients – less than 12 nmol/L. In patients of the group 1 erectile dysfunction was regarded as one of the manifestations of asthenic syndrome and was relatively easily corrected by the administration of PDE-5 inhibitors and antiasthenic therapy. Patients of the group 2 had more severe complaints, «worse» scores on questionnaire scales and more significant asthenic syndrome. Discussion. The possible mechanisms of androgen deficiency and hormonal profile changes in those patients may be a direct damaging of gonadal cells by virus and nonspecific suppression of the hypothalamic-pituitary system caused by a severe illness. In some cases, testosterone preparations were prescribed to those patients to achieve a therapeutic effect. Conclusions. COVID infection may have a negative impact on erectile function. The main causes of this are decrease of testosterone level, endothelial dysfunction, and long-term asthenization. Those changes may be reversible by rehabilitation and drug correction. One should not rush to begin hormone replacement therapy. It makes sense to start treatment with antiasthenic drugs, and add testosterone preparations in the absence of an effect only. This study addresses only some aspects of the COVID-19 influence on the men's health. In the context of the ongoing pandemic and the inevitable increase in the number of ill patients, further comprehensive studies are needed to clarify all the details and organize adequate andrological care for these patients.

Impact of Varicocele and Varicocele Surgery on Semen Quality, Erectile Function and Serum Hormone Levels

2018 ◽  
Vol 1 (1) ◽  
pp. 129-136
Author(s):  
Badereddin Mohamad Al-Ali ◽  
Emma Persad ◽  
Andreas Lunacek ◽  
Christof Mrstik ◽  
Eugen Plas
Keyword(s):  
Testosterone Level ◽  
Erectile Function ◽  
Semen Quality ◽  
Semen Analysis ◽  
Serum Testosterone ◽  
T Test ◽  
Serum Testosterone Level ◽  
Testosterone Levels ◽  
Group 2 ◽  
Group 1

Introduction: Many studies suggest that varicoceles are associated with hypogonadism and varicocele repair can increase testosterone levels and improve erectile function.Aim: The aim of this retrospective study was to analyze the impact of varicocele and varicocele surgery on testosterone level, semen quality, and erectile function.Methods: Our study included 265 infertile males with a clinical varicocele. This group was divided into three groups: group 1 (193) patients who did not receive surgery, group 2 (72 patients) who were operated on according to the Palomo procedure and group 3 (28 patients), who acted as a control group without a varicocele. All patients completed the International Index of Erectile Function IIEF-5 (German version) and underwent semen analysis. Serum testosterone, follicle stimulating hormone (FSH), and luteinizing hormone (LH) were measured at inclusion into the study and after surgery.Main outcome measures: Changes in semen quality, erectile function, and serum hormones after surgery.Results: The IIEF-5 scores in groups 1 and 2 were 21.01 ± 2.2; and 21.74 ± 1 respectively, and the resulting t-test for equality of variance was significant (p < 0.0001). Total testosterone level in groups 1 and 2 were 3.16 ± 0.37 and 3 ± 0.01, respectively, and the resulting t-test for equality of variance was significant (p < 0.0001). The results of the semen analysis were better in group 2 (after surgery) (28.6%, p < 0.001) in comparison to group 1. Interestingly, pre-operative serum testosterone levels were lower in patients with later improvement of semen analysis (p = 0.05). Body mass index (p = 0.8), pre-operative serum FSH (p = 0.9), LH (p = 0.2), and nicotine consumption (p = 0.6) were similar in both the group that saw improvement and the group with no change in semen quality.Conclusion: Semen quality improved in 28.6% of patients after varicocele surgery. Erectile dysfunction (ED) improved after varicocele surgery. We report that lower pre-operative serum testosterone level might be a possible indicator for successful surgical outcome.

Low-Intensity Extracorporeal Shockwave Therapy – A New Approach in the Treatment of Erectile Dysfunction after Radical Prostatectomy

2017 ◽  
Vol 10 (2) ◽  
pp. 104-110
Author(s):  
Boyan A. Stoykov ◽  
Nikolay H. Kolev ◽  
Rumen P.Kotsev ◽  
Fahd Al-Shargabi ◽  
Pencho P. Genov ◽  
...  
Keyword(s):  
Erectile Dysfunction ◽  
Erectile Function ◽  
Control Group ◽  
Nerve Sparing ◽  
Low Intensity ◽  
The Third ◽  
Extracorporeal Shock Wave ◽  
Number Of Patients ◽  
Group 2 ◽  
Group 1

Summary The experience accumulated with low-intensity extracorporeal shock wave therapy (LI-ESWT) from international clinical trials has demonstrated its safety, efficacy and good tolerance in treatment of erectile dysfunction (ED). The aim of this retrospective study was to investigate the effect of LI-ESWT in patients with ED after bilateral nerve sparing radical surgery for prostate cancer. Twenty-seven patients underwent bilateral nerve sparing radical retropubic prostatectomy (BNSRRP) at the clinic of urology of the university hospital in Pleven between January 2016 and December 2016. Twenty-one of these patients had pre-operative preserved erectile function (EF), as reported according to the International Index of Erectile Function (IIEF-5). Postoperatively, these 21 patients experienced a mild (18-21 points) impairment of EF. In 10 patients (group 1), LI-ESWT was performed. The procedure was performed once a week for 6 weeks with a LI-ESWT (BTL 6000 SWT Topline) instrument. The reading was obtained with IIEF-5 on the third and sixth month after the end of therapy. The other 11 patients (group 2) were used as a control group and did not receive treatment. In 5 patients in group 1, a recovery of EF (> 21 points) as per IIEF-5 was recorded at the third month after treatment. In two patients, the same score was recorded at the sixth month. No improvement was seen in three men in group 1. In the controls (group 2), a spontaneous EF improvement in four patients at sixth month was registered. Despite the small number of patients and their short-term follow-up, our initial results indicate that LI-ESWT is effective, safe and well-tolerated. It could be an alternative for early penis rehabilitation in patients who have undergone BNSRRP.

Impact of functional outcomes on long-term quality of life after open retropubic radical prostectomy.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. 9580-9580
Author(s):  
Bjoern Loeppenberg ◽  
Christian von Bodman ◽  
Marko Brock ◽  
Joachim Noldus ◽  
Jueri Palisaar
Keyword(s):  
Quality Of Life ◽  
Erectile Dysfunction ◽  
Erectile Function ◽  
Functional Outcomes ◽  
Term Survival ◽  
Eortc Qlq C30 ◽  
Eortc Qlq ◽  
The Impact

9580 Background: Patients who underwent open retropubic radical prostatectomy (ORRP) for prostate-cancer (PCA) have excellent long-term survival. Besides oncologic safety, recovery of continence and erectile function are highly important, as adverse functional outcomes may have a detrimental effect on health-related quality of life (HRQOL). We report the long-term HRQOL of PCA survivors after ORRP using standardized tools. Methods: Men treated between August 2003 and December 2007 with ORRP for localized PCA at a single academic hospital received validated questionnaires (International consultation on incontinence questionnaire (ICIQ), International index of erectile function (IIEF-5), Erection hardness score (EHS), EORTC QLQ-C30) to assess functional outcomes and HRQOL. Results were correlated with the global-health score (GHS) of the EORTC QLQ-C30 to assess the impact of ORRP on HRQOL. Results: In the study period 1936 men underwent ORRP of whom 1156 (59.7%) received a nerve-sparing (NS) procedure. Questionnaire return-rate was 59% (n=1141) comprising the final study cohort. Median follow-up (FU) was 62 months. Mean age at surgery and FU was 63.7±6.2 and 69.2±6.2 years, respectively. Biochemical recurrence (BCR) occurred in 17.5% (n=200/1141) and 2% (n=40/1936) deceased. Mean GHS in the study population was 71.5±20.8. In the ICIQ 28% (n=320) scored 0 indicating complete continence and 9.9% (n=113) scored ≥11 indicating severe incontinence. The corresponding GHS was 78.1±19.5 and 55.4±21.8, respectively. 68.5% (n=782) of patients used no pads and 17.9% (n=204) ≥2 pads. Corresponding GHS scores were 74.9±19.8 and 58.9±20.7. Using the IIEF-5 in men who received NS, 24.1% (n=154) had no erectile dysfunction versus 50% (n=318) using the EHS. Corresponding GHS scores were 82.2±16.3 and 74.7±19.8, respectively. Patients with BCR had a GHS of 66.8±21.8 versus 72.5±20.5 for patients without. Men who achieved the Trifecta and Pentafecta criteria had a GHS of 83.1±15.1 and 83.3±15, respectively. Conclusions: Incontinence severely impacts the HRQOL of long-term survivors after ORRP while erectile dysfunction and BCR have a lesser effect. Every effort should be undertaken to maintain functional integrity.

Abstract 3012: Impact of Thromboaspiration during Primary PCI on Microvascular Damage and Infarct Size: Acute and Long term ce-MRI Evaluation.

Circulation ◽  
2007 ◽  
Vol 116 (suppl_16) ◽  
Author(s):  
Gennaro Sardella ◽  
Massimo Mancone ◽  
Raffaele Scardala ◽  
Leonardo De Luca ◽  
Chiara Bucciarelli Ducci ◽  
...  
Keyword(s):  
Infarct Size ◽  
Primary Pci ◽  
Microvascular Damage ◽  
St Segment ◽  
Group 2 ◽  
Procedural Outcomes ◽  
The Impact ◽  
Mri Evaluation ◽  
Group 1

Background: In patients with ST-elevatrion myocardial infarction (STEMI), impairment of microcirculatory function is a negative independent predictor of myocardial function recovery. Compared with conventional stenting, thrombectomy during primary percutaneous coronary intervention (PCI) seems to improve the parameters of myocardial tissue perfusion. We sought to evaluate the impact of thromboaspiration on procedural outcomes and microascualr damage and infarct size by contrast enhanced-MRI (ce-MRI) as compared to conventional primary PCI. Methods:We randomized 75 patients (mean age 64.3±10.2, 55 male) referred to our Hospital with a STEMI (<9 hours from symptoms onset) and an occlusive thrombus at basal angiography, to thromboaspiration with a manual device (Export ®-Medtronic (n=38) (group 1)) and standard PCI (n=37) (group 2). 3 days after procedure and 3 months later a ce-MRI was performed to assess the microvascular damage (as hypoenhancement (HO)) and infarct size (as hyperenhancement(HR)) in the 2 groups. The primary end points were the angiographic result in terms of the TIMI ≥ II flow , MBG ≥ 2 and ST-segment resolution (STr)≥ 70% post-stenting and the microvascular damage (grams/g) and infarct size (grams/g) evaluated by ce-MRI. Results: No differences on baseline, clinical and angiographic preprocedural findings were observed between the two groups. After trombectomy, a TIMI II flow was present in in 38.6 vs 19.6% (p=0.054) and TIMI III was 30.7 vs 72.5% (for group 1 and 2, respectively, p<0.001). Postprocedural MBG ≥2 was 70,3% vs 28,7% (p<0.001) and 90′ ST-segment resolution was 80% vs 37.5% (for group 1 and 2, respectively, p<0.001). Ce-MRI showed an HO of 4.04±5.87g at 3 days vs 0.12±0.4g at 3 months (p= 0.04) in group 1, and 3.7±5.04 vs 2.7±2.3 (3 d and 3 m. respectively)(p=ns) in group 2. At 3 days HR was 17.39±15.6g vs 11.01±8.07g at 3 months in group 1 (p=0.04) and 14.02±7.5g vs 13.6±12.7g ( 3 d. and 3 m. respectively) (p=ns) in group 2. Conclusion:Compared with conventional stenting, a pretreatment with thrombectomy during primary PCI, improves epicardial flow and procedural outcomes. The long term ce-MRI evaluation suggests a reduction in microvascular damage and infarct size compared with the acute evaluation in the thrombectomy group.

scholarly journals Impact of Renal Function on Long-Term Clinical Outcomes in Patients With Coronary Chronic Total Occlusions: Results From an Observational Single-Center Cohort Study During the Last 12 Years

2020 ◽  
Vol 7 ◽  
Author(s):  
Lei Guo ◽  
Huaiyu Ding ◽  
Haichen Lv ◽  
Xiaoyan Zhang ◽  
Lei Zhong ◽  
...  
Keyword(s):  
Renal Function ◽  
Renal Insufficiency ◽  
Clinical Outcomes ◽  
Group 4 ◽  
Significant Difference ◽  
Group 3 ◽  
Group 2 ◽  
The Impact ◽  
Group 1

Background: The number of coronary chronic total occlusion (CTO) patients with renal insufficiency is huge, and limited data are available on the impact of renal insufficiency on long-term clinical outcomes in CTO patients. We aimed to investigate clinical outcomes of CTO percutaneous coronary intervention (PCI) vs. medical therapy (MT) in CTO patients according to baseline renal function.Methods: In the study population of 2,497, 1,220 patients underwent CTO PCI and 1,277 patients received MT. Patients were divided into four groups based on renal function: group 1 [estimated glomerular filtration rate (eGFR) ≥ 90 ml/min/1.73 m2], group 2 (60 ≤ eGFR &lt;90 ml/min/1.73 m2), group 3 (30 ≤ eGFR &lt;60 ml/min/1.73 m2), and group 4 (eGFR &lt;30 ml/min/1.73 m2). Major adverse cardiac event (MACE) was the primary end point.Results: Median follow-up was 2.6 years. With the decline in renal function, MACE (p &lt; 0.001) and cardiac death (p &lt; 0.001) were increased. In group 1 and group 2, MACE occurred less frequently in patients with CTO PCI, as compared to patients in the MT group (15.6% vs. 22.8%, p &lt; 0.001; 15.6% vs. 26.5%, p &lt; 0.001; respectively). However, there was no significant difference in terms of MACE between CTO PCI and MT in group 3 (21.1% vs. 28.7%, p = 0.211) and group 4 (28.6% vs. 50.0%, p = 0.289). MACE was significantly reduced for patients who received successful CTO PCI compared to patients with MT (16.7% vs. 22.8%, p = 0.006; 16.3% vs. 26.5%, p = 0.003, respectively) in group 1 and group 2. eGFR &lt; 30 ml/min/1.73 m2, age, male gender, diabetes mellitus, heart failure, multivessel disease, and MT were identified as independent predictors for MACE in patients with CTOs.Conclusions: Renal impairment is associated with MACE in patients with CTOs. For treatment of CTO, compared with MT alone, CTO PCI may reduce the risk of MACE in patients without chronic kidney disease (CKD). However, reduced MACE from CTO PCI among patients with CKD was not observed. Similar beneficial effects were observed in patients without CKD who underwent successful CTO procedures.

scholarly journals THE IMPACT OF VETOM 20.76 BASED ON PREDATORY FUNGUS ARTHROBOTRYS OLIGOSPORA ON THE LEUCOCYTES IN THE GEESE BLOOD

2019 ◽  
pp. 103-108
Author(s):  
N. S. Iakovleva ◽  
G. A. Nozdrin ◽  
M. S. Iakovleva ◽  
S. N. Tishkov ◽  
A. I. Shevchenko
Keyword(s):  
Live Weight ◽  
Control Group ◽  
Group 2 ◽  
The Impact ◽  
Higher Doses ◽  
Leukocyte Concentration ◽  
Experimental Group ◽  
Different Doses ◽  
Group 1

The paper demonstrates the results on the effect of new specimen Vetom 20.76 on concentration of leukocytes in the blood of geese on the basis of the predatory fungus Artusbotus oligospora. In order to achieve the goal of the experiment, one control group and six experimental groups were arranged on the principle of paired analogues. Each group contained 10 geese aged 1 month. The geese from the experimental groups received Vetom 20.76 in different doses in the morning with water once a day: the geese of the 1st experimental group - dose of 0.5 ppm/kg of live weight during 15 days; 2nd experimental group - 1 ppm/kg of live weight during 15 days; 3rd experimental group - 2 ppm/kg of live weight during 15 days, 4th experimental group - 0.5 ppm/kg live weight during 30 days, 5th experimental group - 1 ppm/kg live weight during 30 days and 6th - 2 ppm/kg live weight during 30 days. The geese of control group didn’t receive the specimen. The concentration of leukocytes in the blood of experimental geese increases in the period of specimen application as well as in the period of its aftereffect. If Vetom 20.76 is prescribed for 15 days, the effect of leukopoiesis stimulation finishes on the 30th day. If the specimen is applied during 30 days, the leukocytes in the blood continue to increase up to the 60th day. This long-term application of Vetom 20.76 dosed 0.5ppm/kg increases leucocytes within the physiological norm. Application of higher doses (1 and 2 ppm/kg) the leukocyte concentration conforms to the physiological norm

Whether Adding Vitamin D to Tadalafil 5 mg Treatment Is Useful in Patients with Erectile Dysfunction and Vitamin D Deficiency?

2021 ◽  
pp. 1-6
Author(s):  
Aykut Demirci ◽  
Murat Çakan ◽  
Murat Topçuoğlu
Keyword(s):  
Vitamin D ◽  
Erectile Dysfunction ◽  
Vitamin D Deficiency ◽  
Sexual Desire ◽  
Erectile Function ◽  
Phosphodiesterase Type 5 Inhibitors ◽  
Vitamin D Levels ◽  
Group 2 ◽  
Phosphodiesterase Type ◽  
Group 1

<b><i>Introduction:</i></b> Numerous factors such as endothelial disease and hormonal disorder cause the development of erectile dysfunction (ED). However, the relationship between vitamin D deficiency (VDD) and ED is unclear. Moreover, the benefit of vitamin D replacement on ED patients with VDD is uncertain. As far as we know, there is no study yet in the literature regarding the addition of vitamin D to phosphodiesterase type 5 inhibitors in the treatment of ED patients with VDD. In this study, we investigated whether adding vitamin D to daily tadalafil treatment would be beneficial in ED patients with VDD. <b><i>Methods:</i></b> A total of 111 patients with VDD accompanying ED were retrospectively evaluated between January 2016 and December 2019. Patients were divided into 2 groups according to the treatment they received. Group 1 (<i>n</i> = 58) was treated with daily oral tadalafil 5 mg, while group 2 (<i>n</i> = 53) received oral tadalafil 5 mg and 4,000 IU vitamin D3. Total International Index of Erectile Function-15 (IIEF-15) scores and vitamin D levels of the groups were compared at the end of the study. <b><i>Results:</i></b> The mean vitamin D level was increased statistically significant in group 2, but no difference was seen in group 1 (<i>p</i> &#x3c; 0.001 and <i>p</i> &#x3e; 0.05, respectively). There was a significant increase in median erectile function, orgasmic function, sexual desire, sexual satisfaction, and overall satisfaction scores in both groups (<i>p</i> &#x3c; 0.001). However, the increase in median erectile function and sexual desire scores was significantly higher in group 2 compared to group 1 at the end of the study (<i>p</i> = 0.01 and <i>p</i> &#x3c; 0.001, respectively). <b><i>Conclusion:</i></b> We found that adding vitamin D to 5 mg oral daily tadalafil treatment may have an additional positive effect on erectile function and sexual desire in ED patients with VDD.

Finasteride, not tamsulosin, increases severity of erectile dysfunction and decreases testosterone levels in men with benign prostatic hyperplasia

2015 ◽  
Vol 23 (3) ◽  
Author(s):  
Abdulmaged M. Traish ◽  
Karim Sultan Haider ◽  
Gheorghe Doros ◽  
Ahmad Haider
Keyword(s):  
Erectile Dysfunction ◽  
Benign Prostatic Hyperplasia ◽  
Side Effects ◽  
Adverse Effects ◽  
Erectile Function ◽  
Prostatic Hyperplasia ◽  
Continuous Treatment ◽  
Plasma Testosterone ◽  
The Impact

Abstract5α-reductase inhibitors (5α-RIs) (finasteride and dutasteride) have been proven useful in treatment of lower urinary tract symptoms (LUTS) related to benign prostatic hyperplasia (BPH). However, these inhibitors exert undesirable sexual side effects and, in some cases, these effects are persistent. There is considerable disagreement with regard to whether the adverse side effects resolve with continuous treatment.To investigate the long-term adverse effects of finasteride treatment in men with BPH on erectile function and to compare these adverse effects in men treated with the α1-adrenergic receptor blocker, tamsolusin.In this retrospective registry study, a cohort of 470 men aged between 47 and 68 years (mean 57.78±4.81) were treated with finasteride (5 mg/day). A second cohort of 230 men aged between 52 and 72 years (mean 62.62±4.65) were treated with tamsulosin (0.4 mg). All men were followed up for 45 months. At intervals of 3 months and at each visit, plasma testosterone (T) levels and the international index of erectile function (IIEF-EF) questionnaire scores were determined.Long-term treatment with finasteride therapy is associated with worsening of erectile dysfunction (ED) as shown by the significant decrease in the IIEF-EF scores in men treated with finasteride. No worsening of ED was observed in men treated with tamsulosin. The increase in ED due to finasteride did not resolve with continued treatment with finasteride. Most importantly, long-term finasteride therapy resulted in reduction in total T levels, contributing to a state of hypogonadism. On the contrary, no changes in T levels were noted in men treated with tamsolusin.Our findings suggest that in men with BPH, long-term finasteride therapy but not tamsulosin results in worsening of ED and reduces total T concentrations. Clinicians are urged to discuss the impact of 5α-RIs therapy on sexual function with their patients before commencing this therapy.

scholarly journals Effect of ADMA levels on severity of erectile dysfunction in chronic kidney disease and other risk factors

2016 ◽  
Vol 10 (1-2) ◽  
pp. 41 ◽  
Author(s):  
Kaan Gökçen ◽  
Hakan Kılıçarslan ◽  
Burhan Coşkun ◽  
Alparslan Ersoy ◽  
Onur Kaygısız ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Erectile Dysfunction ◽  
Kidney Disease ◽  
Erectile Function ◽  
Serum Prolactin ◽  
Control Group ◽  
Total Testosterone ◽  
Group 2 ◽  
And Control ◽  
Group 1

Introduction: Hormonal, neurogenic, vasculogenic, and psychogenic impairments, as well as endothelial dysfunction may play a role in erectile dysfunction (ED) in patients with chronic kidney disease (CKD). Asymmetrical dimethylarginine (ADMA) is an inhibitor of nitric oxide, which is the key element of ED. ADMA levels are increased in CKD. We aimed to evaluate the effect of serum ADMA, prolactin, testosterone, and hemoglobin levels on erectile function of patients with CKD and control subjects.Methods: A total of 42 men with CKD and 25 age-matched controls were enrolled. The patients with CKD were categorized into group 1 and group 2 based on whether they had ED according to their response to International Index of Erectile Function questionnaire (IIEF-EFD). Group 3 was a control group. Serum ADMA, total testosterone prolactin, and hemoglobin levels of the patients were evaluated.Results: Serum ADMA, testosterone, and hemoglobin levels were similar between group 1 and 2, serum prolactin level was significantly high in group 1 than in group 2 or 3 (control group). There was no correlation between ADMA levels and IIEF-EFD scores of patients with CKD.Conclusions: The results of this study suggest serum ADMA level is not related with ED in patients with CKD. Also, low testosterone and hemoglobin levels were not significant factors. High levels of serum prolactin are related with ED in patients with CKD.

scholarly journals High visceral adiposity index associated with metabolic syndrome impairs erectile function in sexually active men.

2020 ◽  
Author(s):  
Mustafa Bolat ◽  
Mustafa Latif Özbek ◽  
Bekir Şahin ◽  
Merve YILMAZ ◽  
Fatih Kocamanoğlu ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Sexual Function ◽  
Erectile Function ◽  
Visceral Adiposity Index ◽  
Characteristic Analysis ◽  
The Metabolic Syndrome ◽  
Increased Risk ◽  
Group 2 ◽  
The Impact ◽  
Group 1

Aims:Erectile dysfunction (ED) is a common condition affected by many factors. We aimed to show the impact of the metabolic syndrome (MeTS) on male sexual function based on VAI and the impact of increased levels of the VAI was investigated in patients with ED among the patients with and without MeTS. Methods:Participants who met MeTS criteria (Group 1, n=96) and without MeTS (Group 2, n=189) were included in this cross-sectional study. The MeTS diagnosis was made in the presence of at least three of the following criteria: serum glucose level higher than 100 mg/dl, HDL cholesterol level below 40 mg/dl, triglyceride level greater than 150 mg/dl, waist circumference greater than 102 cm and blood pressure greater than 130/85 mmHg. Demographic data were recorded; biochemical and hormonal tests were measured. Erectile and other sexual function scores were recorded. The VAI was calculated using the [(WC/39.68)+(1.88xMI)]xTG/1.03x1.31/HDL formula. Results:Mean age, smoking volume, T and T/E2 ratios of the groups were similar (p>0.05). Mean VAI was two-fold higher in patients in Group 1 (p<0.001) and erectile function score was lower in Group 1 than Group 2 (p=0.001). Other sexual function scores were similar (p>0.05). The METS was associated with an increased risk of ED (p=0.001). Logistic regression analysis showed that each integer increase of the VAI was associated with a 1.4-fold increased risk of ED (p<0.001). Higher T values were associated with a better erectile function (p=0.03). For the VAI=4.33, receiver-operating characteristic analysis showed a sensitivity of 89.6 % and specificity of 57.7 %. Conclusion:Compared to non-MeTS, the presence of MeTS has emerged as a risk factor for patients with ED with high VAI levels while the other sexual functions are preserved. Management of ED patients with MeTS should cover a comprehensive metabolic and endocrinological evaluation in addition to andrological work up.

Sign in / Sign up

Export Citation Format

Share Document